BMS 986165

Drug Profile

BMS 986165

Alternative Names: BMS986165

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies
  • Mechanism of Action TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis
  • Phase I Autoimmune disorders; Psoriasis
  • Preclinical Inflammatory bowel diseases; Systemic lupus erythematosus

Most Recent Events

  • 29 Aug 2017 Bristol-Myers Squibb plans a phase I trial in Healthy volunteers in USA (NCT03262727)
  • 23 Aug 2017 NCT03252431 plans a phase II trial for Systemic lupus erythematosus in USA, Argentina, Bulgaria, Colombia, France, Germany, Hungary, Israel, Japan, South Korea, Poland, Romania, Russia, Taiwan and Ukraine (NCT03252587)
  • 21 Aug 2017 Bristol-Myers Squibb plans a phase I bioavailability trial in Healthy subjects in the Netherlands (NCT03254784)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top